{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Uveal Melanoma: Current Treatments & New Approaches on the Horizon

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Explain research challenges to establishing a standard of care for the treatment of patients with uveal melanoma.
  2. Analyze results from two phase II clinical trials evaluating the use of nivolumab and ipilimumab in the treatment of uveal melanoma.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT0321
Published: March 2021
Expires: 3/3/2023
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Catlin Nalley
Topics: Melanoma